Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

被引：0

作者：

Aggarwal, Piyush ^{[1
]}

Gunasekaran, Vinisha ^{[1
]}

Sood, Ashwani ^{[1
]}

Kumar, Narendra ^{[2
]}

Rathore, Yogesh ^{[1
]}

Kumar, Rajender ^{[1
]}

Mittal, Bhagwant Rai ^{[1
]}

机构：

[1] Postgrad Inst Med Educ & Res, Dept Nucl Med, Chandigarh 160012, India

[2] Postgrad Inst Med Educ & Res, Dept Radiotherapy, Chandigarh, India

来源：

CLINICAL NUCLEAR MEDICINE | 2025年 / 50卷 / 03期

关键词：

Lu-177-PSMA-617; prostatic neoplasms; castration-resistant; treatment outcome; disease progression; rechallenge;

D O I：

10.1097/RLU.0000000000005589

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Lu-177-PSMA-617 radioligand therapy has been US Food and Drug Administration-approved safe and effective treatment modality for metastatic castration-resistant prostate cancer, usually administered in 4 to 6 cycles at 6 to 8 weeks apart. Many patients achieve partial response or stable disease with biochemical response after treatment. However, these effects are usually short-lived, and patients ultimately show disease progression after a median period of 6 to 9 months. Rechallenge therapy appears to be safe and effective treatment modality in such patients. We show the clinical efficacy and safety of re-rechallenge Lu-177-PSMA radioligand therapy in a 64-year-old man with metastatic castration-resistant prostate cancer with disease progression on multiple lines of hormonal and chemotherapy treatment.

引用

页码：231 / 233

页数：3

共 8 条

[1] The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study [J].

Ahmadzadehfar, Hojjat ;

Matern, Ralf ;

Baum, Richard P. ;

Seifert, Robert ;

Kessel, Katharina ;

Boegemann, Martin ;

Kratochwil, Clemens ;

Rathke, Hendrik ;

Ilhan, Harun ;

Svirydenka, Hanna ;

Sathekge, Mike ;

Kabasakal, Levent ;

Yordanova, Anna ;

Garcia-Perez, Francisco Osvaldo ;

Kairemo, Kalevi ;

Maharaj, Masha ;

Paez, Diana ;

Virgolini, Irene ;

Rahbar, Kambiz .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (12) :4067-4076

[2] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer [J].

Derlin, Thorsten ;

Widjaja, Liam ;

Werner, Rudolf A. ;

Bengel, Frank M. .

JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) :54-58

[3] Early Experience of Rechallenge 177Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer [J].

Gafita, Andrei ;

Rauscher, Isabel ;

Retz, Margitta ;

Knorr, Karina ;

Heck, Matthias ;

Wester, Hans-Juergen ;

D'Alessandria, Calogero ;

Weber, Wolfgang A. ;

Eiber, Matthias ;

Tauber, Robert .

JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) :644-648

[4] Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial [J].

Hofman, Michael S. ;

Emmett, Louise ;

Sandhu, Shahneen ;

Iravani, Amir ;

Buteau, James P. ;

Joshua, Anthony M. ;

Goh, Jeffrey C. ;

Pattison, David A. ;

Tan, Thean Hsiang ;

Kirkwood, Ian D. ;

Ng, Siobhan ;

Francis, Roslyn J. ;

Gedye, Craig ;

Rutherford, Natalie K. ;

Weickhardt, Andrew ;

Scott, Andrew M. ;

Lee, Sze-Ting ;

Kwan, Edmond M. ;

Azad, Arun A. ;

Ramdave, Shakher ;

Redfern, Andrew ;

Macdonald, William ;

Guminski, Alex ;

Hsiao, Edward ;

Chua, Wei ;

Lin, Peter ;

Zhang, Alison Yan ;

Stockler, Martin R. ;

Williams, Scott G. ;

Martin, Andrew J. ;

Davis, Ian D. .

LANCET ONCOLOGY, 2024, 25 (01) :99-107

[5] Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer [J].

Mader, Nicolai ;

Ngoc, Christina Nguyen ;

Kirkgoeze, Bilge ;

Baumgarten, Justus ;

Groener, Daniel ;

Klimek, Konrad ;

Happel, Christian ;

Tselis, Nikolaos ;

Chun, Felix K. H. ;

Gruenwald, Frank ;

Sabet, Amir .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (06) :1811-1821

[6] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer [J].

Sartor, Oliver ;

de Bono, Johann ;

Chi, Kim N. ;

Fizazi, Karim ;

Herrmann, Ken ;

Rahbar, Kambiz ;

Tagawa, Scott T. ;

Nordquist, Luke T. ;

Vaishampayan, Nitin ;

El-Haddad, Ghassan ;

Park, Chandler H. ;

Beer, Tomasz M. ;

Armour, Alison ;

Perez-Contreras, Wendy J. ;

DeSilvio, Michelle ;

Kpamegan, Euloge ;

Gericke, Germo ;

Messmann, Richard A. ;

Morris, Michael J. ;

Krause, Bernd J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12) :1091-1103

[7] Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study [J].

Seifert, Robert ;

Telli, Tugce ;

Lapa, Constantin ;

Desaulniers, Melanie ;

Hekimsoy, Turkay ;

Weber, Wolfgang A. ;

Pfob, Christian ;

Hadaschik, Boris ;

Boegemann, Martin ;

Schaefers, Michael ;

Herrmann, Ken ;

Rahbar, Kambiz ;

Eiber, Matthias ;

Fendler, Wolfgang P. .

JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (06) :909-916

[8] Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer [J].

Yordanova, Anna ;

Linden, Paula ;

Hauser, Stefan ;

Meisenheimer, Michael ;

Kuerpig, Stefan ;

Feldmann, Georg ;

Gaertner, Florian C. ;

Essler, Markus ;

Ahmadzadehfar, Hojjat .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (05) :1073-1080

← 1 →